EuBiologics Co., Ltd. (KOSDAQ:206650)
South Korea · Delayed Price · Currency is KRW 11,060
-90 (-0.81%)
Jan 19, 2026, 3:30 PM KST
EuBiologics Revenue
In the year 2024, EuBiologics had annual revenue of 96.04B KRW with 38.45% growth. EuBiologics had revenue of 26.89B in the quarter ending December 31, 2023, with 54.38% growth.
Revenue
96.04B
Revenue Growth
+62.39%
P/S Ratio
4.22
Revenue / Employee
n/a
Employees
n/a
Market Cap
405.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 96.04B | 26.67B | 38.45% |
| Dec 31, 2023 | 69.37B | 13.90B | 25.06% |
| Dec 31, 2022 | 55.47B | 16.08B | 40.83% |
| Dec 31, 2021 | 39.38B | 10.90B | 38.24% |
| Dec 31, 2020 | 28.49B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |